A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A gynecologic oncology group study

Morrow, C. Paul; d'Ablaing, Gerrit; Brady, Luther W.; Blessing, John A.; Hreshchyshyn, Myroslaw M.

doi:10.1016/0090-8258(84)90039-8

Cited by 87 publications

(64 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Carcinosarcomas have also been considered to be anaplastic epithelial tumors arising from the mullerian epithelium, with metaplasia developing from stroma-like sarcomatous elements [6], suggesting that the tumors should be treated as epithelial ovarian malignancies. Approximately 70% of patients with carcinosarcomas present at clinically advanced stages (stage III or IV); most of these patients experience recurrence and die within a short period of time [7,8]. Thus, 77.5% of our patients presented with advanced tumors, similar to previous reports.…”

Section: Discussionsupporting

confidence: 76%

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Chun

Kim²,

Kim³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: There have been only a few reports on the survival and management of patients with ovarian carcinosarcomas. We evaluated the clinical characteristics, outcomes and prognostic factors of ovarian carcinosarcomas. Methods: Retrospective analysis of data obtained from medical records of 40 patients treated at the Asan Medical Center, Seoul, Korea, between January 1989 and January 2008. Results: Median survival was significantly longer in patients <60 years of age than in those ≧60 (p = 0.001), patients with early-stage compared to advanced tumors (p = 0.035), those with optimally debulked tumors compared to suboptimally (p < 0.001) in the advanced stage, and patients treated with paclitaxel/platinum compared to patients treated with other chemotherapies (p < 0.001). The progression-free interval was longer in patients with early-stage (p = 0.003) and optimally debulked tumors (p = 0.001), as well as in those treated with paclitaxel/platinum (p = 0.049). Multivariate analysis showed that advanced-stage, non-optimal debulking and non-paclitaxel/platinum chemotherapy were significant independent predictors of a shorter progression-free interval, and that non-optimal debulking and non-paclitaxel/platinum chemotherapy were significant independent predictors of shorter overall survival. Conclusions: Early-stage optimal debulking and adequate chemotherapy can influence time to progression and survival, indicating that the most effective treatment for patients with ovarian carcinosarcomas consists of optimal debulking surgery followed by paclitaxel/platinum chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 76%

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Chun

Kim²,

Kim³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…Although heterologous carcinosarcomas were reported as a negative prognostic factor in many studies, sarcomatous subtypes were not found to be a prognostic factor in others (2,3,(12)(13)(14)(15). In this study, we also did not find sarcomatous subtypes to be a prognostic factor.…”

Section: Discussionsupporting

confidence: 61%

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

et al. 2016

View full text Add to dashboard Cite

“…The majority of women who present with MMT are postmenopausal with a median age at diagnosis of 66–69 years. MMT are malignant, present at advanced stage (>80%) and the 2-year survival is less than 20% [43, 44, 45, 46, 47, 48]. Complete surgical resection gives the only real chance of cure [49].…”

Section: Malignant Mixed Mesodermal Tumoursmentioning

confidence: 99%

Management of Non-Epithelial Ovarian Tumours

Bridgewater

Rustin²

1999

Oncology

View full text Add to dashboard Cite

Ovarian tumours of non-epithelial origin are less common than those of epithelial origin but must be distinguished from these as their natural history and management differ. As these tumours are rare, histological review by an expert in the field is essential. There have been no randomised trials to outline the management of these tumours and therefore this paper represents a review of descriptive data. Non-epithelial ovarian tumours, which represent approximately 50% of all ovarian tumours and approximately 25% of malignant ovarian tumours, are outlined. Lymphomas and metastatic tumours should be treated the same as when found in other sites and will not be discussed further.

show abstract

A clinical and pathologic study of 30 cases of malignant mixed mullerian epithelial and mesenchymal ovarian tumors: A gynecologic oncology group study

Cited by 87 publications

References 5 publications

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Optimal Debulking Surgery Followed by Paclitaxel/Platinum Chemotherapy Is Very Effective in Treating Ovarian Carcinosarcomas: A Single Center Experience

Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas

Management of Non-Epithelial Ovarian Tumours

Contact Info

Product

Resources

About